Watchlist

Watchlist
Agenus Inc. (AGEN)
Agenus (AGEN) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
The following slide deck was published by Agenus in conjunction with this Read more …
Agenus Receives License Fee of $4 Million USD from Merck
LEXINGTON, Mass. , Nov. 15, 2017 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, today announced the receipt of a $4 million payment for the advancement of an undisclosed antibody unde…
Planned equity offering roundup - healthcare
Recent SEC filings for planned equity offerings by healthcare firms: More news on: CHECKPOINT THERAPEUTICS, Citius Pharmaceuticals Inc., CRISPR Therapeutics, Healthcare stocks news, Read more …
Agenus To Present on Lead Antibody Programs AGEN1884 (CTLA-4) and AGEN2034 (PD-1) at SITC 2017
LEXINGTON, Mass. , Nov. 9, 2017 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced that data on AGEN1884 (CTLA-4) and AGEN2034 (PD-1) demonstrated that the molecules achieved the …
Agenus to Present at the Jefferies Global Healthcare Conference in London
LEXINGTON, Mass. , Nov. 8, 2017 /PRNewswire/ --Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced today that Jennifer Buell , Ph.D., Chief Communications and External Affairs Officer at Agenus, and …
Agenus' (AGEN) CEO Garo Armen on Q3 2017 Results - Earnings Call Transcript
Agenus (AGEN) Q3 2017 Earnings Conference Call November 07, 2017 11:00 AM ET Executives Jennifer Buell Head-Communications and External Affairs Garo Armen Chairman and Chief Executive Officer Jean-Marie Cuillerot Chief Medical Officer Alex Duncan &#x2…
Agenus misses by $0.03, misses on revenue
Agenus (NASDAQ: AGEN ): Q3 EPS of -$0.37 misses by $0.03 . More news on: Agenus, Earnings news and commentary, Healthcare stocks news, Read more …
Agenus Reports Third Quarter 2017 Financial Results and Provides Corporate Update
LEXINGTON, Mass. , Nov. 7, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies and cancer vaccines, provided a corporate update and reported financial results for the third quarter ended September 30, 2017 . …
Notable earnings before Tuesday's open
AAWW , AFMD , AGEN , ALLT , ASIX , ATHM , ATRO , ATRS , BCRX , BLD , CBM , CBOE , CCE , CRIS , CROX , DEA , DF , DNR , EMR , EXPD , GLDD , HAE , HAIN , HCN , HL , HLNE , IONS , JELD , LABL , LGIH , LNCE , LXP , MTRX , MZOR , NS , ONCE , PNK , PRIM , RC…
Your Daily Pharma Scoop: Gilead In NASH, Geron Gets A Boost, AstraZeneca's Oncology Portfolio
This abridged Daily Scoop is published by Avisol Capital Partners, which runs the physician-managed Total Pharma Tracker healthcare investment research service on Seeking Alpha Marketplace. Please click here or scroll down below to read an important announcement about chan…
Agenus to Report Third Quarter 2017 Financial Results on November 7, 2017 and Host Conference Call and Webcast
LEXINGTON, Mass. , Oct. 26, 2017 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines,will release its third quarter 2017 financial results before the market opens on Tuesday, November 7, 2017 . A…
Agenus Inc. (AGEN)